Myocardial Fibrosis and Cardiomyopathy Risk: A Genetic Link in the MESA

• DOI: 10.1161/circheartfailure.122.010262
• Publication Date: 2023-08-01T09:00:37Z
• Authors: Mahsima Shabani; Min Wang; Gregory D. Jenkins; Jerome I. Rotter; Stephen S. Rich; Anthony Batzler; Kent D. Taylor; Josyf C. Mychaleckyj; Duan Liu; Joao A.C. Lima; Naveen L. Pereira
• Keywords: Cardiomyopathy, Dilated; 0301 basic medicine; Cardiomyopathy; Medical Physiology; Left; 610; heart failure; Magnetic Resonance Imaging, Cine; Contrast Media; Cardiorespiratory Medicine and Haematology; Cardiovascular; Cardiovascular medicine and haematology; Ventricular Function, Left; 03 medical and health sciences; Rare Diseases; Clinical Research; Medical physiology; Cardiovascular Medicine and Haematology; fibroblasts; 616; Dilated; Genetics; 2.1 Biological and endogenous factors; Ventricular Function; magnetic resonance imaging; Humans; Minority Health; genetics; risk; Heart Failure; Biomedical and Clinical Sciences; Myocardium; fibrosis; Cardiomyopathy, Hypertrophic; Magnetic Resonance Imaging; Fibrosis; Health Disparities; Heart Disease; Cardiovascular System & Hematology; Cine; Hypertrophic; Biochemistry and Cell Biology; Cardiomyopathies; cardiomyopathy

BACKGROUND: Common genetic variants are associated with risk for hypertrophic cardiomyopathy and dilated cardiomyopathy and with left ventricular (LV) traits. Whether these variants are associated with myocardial fibrosis, an important pathophysiological mediator of cardiomyopathy, is unknown.

METHODS: Multi-Ethnic Study of Atherosclerosis participants with T1-mapping cardiac magnetic resonance imaging in-whom extracellular volume was assessed, and genotyping information was available were included (N=1255). Log extracellular volume (%) was regressed on 50 candidate single nucleotide polymorphisms (previously identified to be associated with hypertrophic cardiomyopathy, dilated cardiomyopathy, and LV traits) adjusting for age, sex, diabetes, blood pressure, and principal components of ancestry. Ancestry-specific results were pooled by fixed-effect meta-analyses. Gene knockdown experiments were performed in human cardiac fibroblasts.

RESULTS:

The SMARCB1 rs2186370 intronic variant (minor allele frequency: 0.18 in White and 0.50 in Black participants), previously identified as a risk variant for dilated cardiomyopathy and hypertrophic cardiomyopathy, was significantly associated with increased extracellular volume ( P= 0.0002) after adjusting for confounding clinical variables. The SMARCB1 rs2070458 locus previously associated with increased LV wall thickness and mass was similarly significantly associated with increased extracellular volume ( P= 0.0002). The direction of effect was similar in all 4 ancestry groups, but the effect was strongest in Black participants. The variants are strong expression quantitative loci in human LV tissue and associated with genotype-dependent decreased expression of SMARCB1 ( P= 7.3×10 -22 ). SMARCB1 knockdown in human cardiac fibroblasts resulted in increased TGF (transforming growth factor)-β1–mediated α-smooth muscle actin and collagen expression.

CONCLUSIONS:

Common genetic variation in SMARCB1 previously associated with risk for cardiomyopathies and increased LV wall thickness is associated with increased cardiac magnetic resonance imaging–based myocardial fibrosis and increased TGF-β1 mediated myocardial fibrosis in vitro. Whether these findings suggest a pathophysiologic link between myocardial fibrosis and cardiomyopathy risk remains to be proven.